Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;44(4):259-260.
doi: 10.1007/s00292-023-01190-9. Epub 2023 Mar 17.

[The biomarker PIK3CA in tumor pathology]

[Article in German]
Ulrich Lehmann  1 , Albrecht Stenzinger  2
Affiliations

[The biomarker PIK3CA in tumor pathology]

[Article in German]
Ulrich Lehmann et al. Pathologie (Heidelb). 2023 Jul.
No abstract available

PubMed Disclaimer

References

Literatur

    1. Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of action and therapeutic targeting. Nat Rev Cancer 15:7–24 - DOI - PubMed - PMC
    1. André F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929–1940 - DOI - PubMed
    1. Narayan P, Prowell TM, Gao JJ et al (2021) FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res 27:1842–1849 - DOI - PubMed
    1. https://www.ema.europa.eu/en/documents/overview/piqray-epar-medicine-ove... . Zugegriffen: 12.01.2023
    1. Rugo HS, Raskin K, Schrock AB et al (2022) Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-2115 - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources